What is the recommended treatment regimen for familial hypercholesterolemia?

Treatment of Familial Hypercholesterolemia

Start with a high-potency statin immediately at diagnosis, rapidly uptitrate to maximum tolerated dose, add ezetimibe within 8 weeks if LDL-C goals are not met, and add a PCSK9 inhibitor within a further 8 weeks if needed—this sequential, aggressive approach is essential to prevent premature atherosclerotic cardiovascular disease and early mortality. 1

Treatment Algorithm by FH Type

Heterozygous FH (HeFH)

Initial Therapy:

• Begin with a high-potency statin (atorvastatin or rosuvastatin) at the highest approved dose for the patient's age 1
• Initiate treatment at diagnosis, ideally by age 8-10 years in children 1
• Combine with heart-healthy lifestyle counseling from the start 1

LDL-C Treatment Goals:

• Primary goal: ≥50% reduction from baseline LDL-C 1
• Alternative goals based on risk:
  • <2.5 mmol/L (<100 mg/dL) if no additional ASCVD risk factors 1
  • <1.8 mmol/L (<70 mg/dL) with imaging evidence of ASCVD or additional major risk factors 1
  • <1.4 mmol/L (<55 mg/dL) with previous ASCVD event 1

Sequential Add-On Therapy:

1. Within 8 weeks: Add ezetimibe 10 mg daily if statin alone doesn't achieve goals 1
2. Consider bile acid sequestrants (colesevelam) as additional therapy if tolerated 1
3. Within 8-16 weeks total: Add PCSK9 inhibitor (evolocumab or alirocumab) if still not at goal on maximal statin + ezetimibe 1, 2

High-Risk Patients: For those with symptomatic ASCVD or multivessel coronary disease, strongly consider triple therapy (high-potency statin + ezetimibe + PCSK9 inhibitor) as first-line treatment rather than sequential escalation 1

Homozygous FH (HoFH)

Critical Timing:

• Begin treatment at diagnosis, ideally by age 2 years 1
• This is a medical emergency requiring immediate specialist referral 3

LDL-C Treatment Goals:

• <2.5 mmol/L (<100 mg/dL) without ASCVD or major risk factors 1
• <1.8 mmol/L (<70 mg/dL) with imaging evidence of ASCVD or additional risk factors 1
• <1.4 mmol/L (<55 mg/dL) with previous ASCVD event 1

Aggressive Sequential Therapy:

1. Immediately: High-potency statin at maximum approved dose with rapid uptitration 1
2. Within 8 weeks: Add ezetimibe 10 mg daily 1
3. Consider: Colesevelam if tolerated 1
4. Within further 8 weeks: Add PCSK9 inhibitor (evolocumab) in patients WITHOUT biallelic LDLR null mutations—continue only if ≥15% additional LDL-C reduction achieved 1
5. By age 3 years (no later than age 8): Initiate lipoprotein apheresis if goals not achieved with maximal medical therapy 1

Advanced Therapies for Inadequate Response:

• Lomitapide (microsomal triglyceride transfer protein inhibitor): Add when conventional therapy insufficient or to reduce apheresis frequency 1, 3, 4
• Evinacumab (ANGPTL3 inhibitor): Consider in patients with markedly elevated LDL-C despite conventional therapy or rapidly progressive ASCVD, especially effective in LDLR-null patients 1, 5, 4
• Combination approach: Recent evidence shows that multimodal therapy (statin + ezetimibe + apheresis + lomitapide + evinacumab) can achieve secondary prevention LDL-C targets even in LDLR-null HoFH 4

Monitoring and Safety

Pre-Treatment Assessment:

• Measure liver enzymes, creatine kinase, glucose, and creatinine before starting statins 1

Ongoing Monitoring:

• Monitor liver enzymes, muscle enzymes, and glucose as in adults 1
• Check LDL-C levels to assess response (non-fasting samples acceptable in stable patients) 1
• Monitor growth in children annually 1
• Assess adherence to lifestyle and medications annually 1

Critical Pitfalls to Avoid

1. Don't delay treatment: Waiting to start therapy or using inadequate doses allows cumulative LDL-C exposure and irreversible atherosclerosis
2. Don't stop at statin monotherapy: Most FH patients require combination therapy to reach goals 1
3. Don't wait too long between escalations: The 8-week timeframe for adding therapies is evidence-based—prolonged delays worsen outcomes 1
4. Don't assume PCSK9 inhibitors work in all HoFH: They require residual LDLR activity; patients with biallelic null mutations need alternative therapies like evinacumab 1, 5
5. Don't forget cascade screening: All first-degree relatives must be screened to identify additional affected family members 1

Special Populations

Pediatric Patients:

• Use statins approved for pediatric use in the relevant jurisdiction 1
• PCSK9 inhibitors have limited long-term safety data in children—use with caution 1
• Evinacumab shows promise in pediatric HoFH but evidence remains limited 5

Adolescent Girls:

• Provide contraception counseling and pregnancy planning advice 1
• Discuss lipid-lowering medication use in pregnancy 1

Highest-Risk Patients:

• Those with diabetes, hypertension, elevated Lp(a), or parental history of premature ASCVD require more aggressive targets 1, 2
• Consider cardiovascular imaging (CT coronary angiography, carotid ultrasound, echocardiography) to assess disease severity and guide treatment intensity 1